Literature DB >> 14576382

Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review.

Parveen Rashid1, Jo Leonardi-Bee, Philip Bath.   

Abstract

BACKGROUND: High blood pressure is a risk factor for stroke recurrence. We assessed the effectiveness of lowering blood pressure in preventing recurrent vascular events in patients with previous stroke or transient ischemic attack. SUMMARY OF REVIEW: We performed a systematic review and meta-regression of completed randomized controlled trials that investigated the effect of lowering blood pressure on recurrent vascular events in patients with prior ischemic or hemorrhagic stroke or transient ischemic attack. Trials were identified from searches of 3 electronic databases (Cochrane Library, EMBASE, MEDLINE). Seven randomized controlled trials, with 8 comparison groups, were included. Lowering blood pressure or treating hypertension with a variety of antihypertensive agents reduced stroke (odds ratio [OR], 0.76; 95% CI, 0.63 to 0.92), nonfatal stroke (OR, 0.79; 95% CI, 0.65 to 0.95), myocardial infarction (OR, 0.79; 95% CI, 0.63 to 0.98), and total vascular events (OR, 0.79; 95% CI, 0.66 to 0.95). No effect was seen on vascular or all-cause mortality. Heterogeneity was present for several outcomes and was partly related to the class of antihypertensive drugs used; angiotensin-converting enzyme inhibitors and diuretics separately, and especially together, reduced vascular events, while beta-receptor antagonists had no discernable effect. The reduction in stroke was related to the difference in systolic blood pressure between treatment and control groups (P=0.002).
CONCLUSIONS: Evidence from randomized controlled trials supports the use of antihypertensive agents in lowering blood pressure for the prevention of vascular events in patients with previous stroke or transient ischemic attack. Vascular prevention is associated positively with the magnitude by which blood pressure is reduced.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576382     DOI: 10.1161/01.STR.0000092488.40085.15

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  127 in total

1.  Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke.

Authors:  Meng Lee; Jeffrey L Saver; Keun-Sik Hong; Qing Hao; Jessica Chow; Bruce Ovbiagele
Journal:  Stroke       Date:  2011-11-03       Impact factor: 7.914

2.  Evaluating Diabetes Outcomes and Costs Within an Ambulatory Setting: A Strategic Approach Utilizing a Clinical Decision Support System.

Authors:  Victoria Oxendine; Albert Meyer; Paula V Reid; Ashley Adams; Valerie Sabol
Journal:  Clin Diabetes       Date:  2014-07

3.  Differences in the role of black race and stroke risk factors for first vs. recurrent stroke.

Authors:  George Howard; Brett M Kissela; Dawn O Kleindorfer; Leslie A McClure; Elsayed Z Soliman; Suzanne E Judd; J David Rhodes; Mary Cushman; Claudia S Moy; Kara A Sands; Virginia J Howard
Journal:  Neurology       Date:  2016-01-20       Impact factor: 9.910

4.  [Recommendations of the European Stroke Initiative for the diagnosis and treatment of spontaneous intracerebral haemorrhage].

Authors:  S Külkens; P Ringleb; J Diedler; W Hacke; T Steiner
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 5.  How to formulate research recommendations.

Authors:  Polly Brown; Klara Brunnhuber; Kalipso Chalkidou; Iain Chalmers; Mike Clarke; Mark Fenton; Carol Forbes; Julie Glanville; Nicholas J Hicks; Janet Moody; Sara Twaddle; Hazim Timimi; Pamela Young
Journal:  BMJ       Date:  2006-10-14

Review 6.  Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.

Authors:  Ehete Bahiru; Angharad N de Cates; Matthew Rb Farr; Morag C Jarvis; Mohan Palla; Karen Rees; Shah Ebrahim; Mark D Huffman
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

7.  Activation of the ACE2/Ang-(1-7)/Mas pathway reduces oxygen-glucose deprivation-induced tissue swelling, ROS production, and cell death in mouse brain with angiotensin II overproduction.

Authors:  J Zheng; G Li; S Chen; J Bihl; J Buck; Y Zhu; H Xia; E Lazartigues; Y Chen; J E Olson
Journal:  Neuroscience       Date:  2014-05-09       Impact factor: 3.590

8.  Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.

Authors:  David J Heal; Jane Gosden; Sharon L Smith
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

9.  Blood pressure declines and less favorable outcomes in the NINDS tPA stroke study.

Authors:  Brian Silver; Mei Lu; Daniel C Morris; Panayiotis D Mitsias; Christopher Lewandowski; Michael Chopp
Journal:  J Neurol Sci       Date:  2008-05-02       Impact factor: 3.181

10.  [Prevention of stroke: what is evidence based?].

Authors:  S Lüders; J Schrader
Journal:  Internist (Berl)       Date:  2009-12       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.